{
    "clinical_study": {
        "@rank": "151291", 
        "arm_group": [
            {
                "arm_group_label": "Evacetrapib (Renal)", 
                "arm_group_type": "Experimental", 
                "description": "Part A: 130 mg evacetrapib administered once, orally to participants with severe renal impairment"
            }, 
            {
                "arm_group_label": "Evacetrapib (Healthy)", 
                "arm_group_type": "Experimental", 
                "description": "Part B: 130 mg evacetrapib administered once, orally, to participants with normal renal function"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to measure how much of the study drug, evacetrapib, gets into\n      the blood stream and how long it takes the body to get rid of it when given to participants\n      with severe renal (kidney) impairment compared to participants with normal renal (kidney)\n      function. This study will last approximately 8 weeks."
        }, 
        "brief_title": "A Study of Evacetrapib (LY2484595) in Participants With Kidney Impairment and in Healthy Participants", 
        "completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "condition": "Cardiovascular Disease", 
        "condition_browse": {
            "mesh_term": "Cardiovascular Diseases"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Female participants are not of child-bearing potential\n\n          -  Have a body mass index of 18 to 40 kilograms per square meter (kg/m^2)\n\n          -  Participants with normal renal function - healthy as determined by medical history,\n             physical examination, and other screening procedures, with normal renal function\n             (assessed by estimated creatinine clearance [CLcr] greater than or equal to 90\n             milliliter  per minute [mL/min] at screening)\n\n          -  Participants with severe renal impairment - estimated CLcr less than 30 mL/min at\n             screening and are not undergoing hemodialysis\n\n        Exclusion Criteria:\n\n          -  Have a history or presence of cardiovascular, respiratory, hepatic, renal,\n             gastrointestinal, endocrine, hematological, or neurological disorders capable of\n             significantly altering the absorption, metabolism, or elimination of drugs; of\n             constituting a risk when taking the study medication; or of interfering with the\n             interpretation of data.\n\n          -  Participants who are unwilling to comply with the dietary requirements/restrictions\n             during the study\n\n          -  Hemoglobin less than 9 grams/deciliter (g/dL) or significant active hematological\n             disease from causes other than underlying renal disease"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "85 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01825889", 
            "org_study_id": "14620", 
            "secondary_id": "I1V-MC-EIAR"
        }, 
        "intervention": {
            "arm_group_label": [
                "Evacetrapib (Renal)", 
                "Evacetrapib (Healthy)"
            ], 
            "description": "Administered orally", 
            "intervention_name": "Evacetrapib", 
            "intervention_type": "Drug", 
            "other_name": "LY2484595"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "October 30, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33014"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orlando", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32806"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Paul", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55114"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Pharmacokinetics of Evacetrapib (LY2484595) Following Administration to Subjects With Impaired Renal Function", 
        "overall_official": {
            "affiliation": "Eli Lilly and Company", 
            "last_name": "1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve from Time Zero to Time T, Where T is the Last Time Point with a Measurable Concentration (AUC[0-Tlast]) of Evacetrapib", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose up to 336 hours post-dose"
            }, 
            {
                "measure": "Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve from Zero to Infinity (AUC[0-\u221e]) of Evacetrapib", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose up to 336 hours post-dose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01825889"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Pharmacokinetic (PK): Maximum Concentration (Cmax) of Evacetrapib", 
            "safety_issue": "No", 
            "time_frame": "Pre-dose up to 336 hours post-dose"
        }, 
        "source": "Eli Lilly and Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}